Stellest Lenses + atropine

**Stellest Lenses + atropine** is a combination therapy for **myopia control in children**, consisting of Stellest spectacle lenses (a brand of myopia control eyeglasses using Highly Aspherical Lenslet Target (HALT) technology) and low-concentration atropine eye drops (typically 0.01%-0.05%). - **Stellest lenses** use hundreds of micro-lenslets arranged in concentric rings to induce myopic defocus on the retina, thought to slow the excessive eye growth responsible for myopia progression. - **Atropine** is a nonselective muscarinic acetylcholine receptor antagonist, delivered as an ophthalmic solution. Even at low concentrations (≤0.05%), it is effective in inhibiting myopia progression; the likely mechanism involves alteration of signaling within the retina and sclera, reducing eye elongation[3][7][1]. - The **combination** targets myopia progression via *two distinct mechanisms*—optical defocus and muscarinic blockade. - Clinical studies demonstrate that **combination therapy is generally more effective** than monotherapy in slowing both spherical equivalent error (SE) and axial length (AL) progression in children[3][7][1]. - Major developers include EssilorLuxottica (Stellest lenses) and pharmaceutical suppliers of atropine formulations. The combination is used off-label and is not itself a regulated or branded product.

Brand names

Stellest

Other names

Stellest Lenses and low-dose atropineStellest Lenses with atropineHALT lens + atropine